202 related articles for article (PubMed ID: 37680638)
21. Dynamic Changes in PD-L1 Expression and Immune Infiltrates Early During Treatment Predict Response to PD-1 Blockade in Melanoma.
Vilain RE; Menzies AM; Wilmott JS; Kakavand H; Madore J; Guminski A; Liniker E; Kong BY; Cooper AJ; Howle JR; Saw RPM; Jakrot V; Lo S; Thompson JF; Carlino MS; Kefford RF; Long GV; Scolyer RA
Clin Cancer Res; 2017 Sep; 23(17):5024-5033. PubMed ID: 28512174
[No Abstract] [Full Text] [Related]
22. Tumoral Melanosis in the Setting of Targeted Immunotherapy for Metastatic Melanoma-A Single Institutional Experience and Literature Review.
Jurgens A; Guru S; Guo R; Brewer J; Bridges A; Jakub J; Comfere N
Am J Dermatopathol; 2021 Jan; 43(1):9-14. PubMed ID: 32149829
[TBL] [Abstract][Full Text] [Related]
23. Durable complete responses off all treatment in patients with metastatic malignant melanoma after sequential immunotherapy followed by a finite course of BRAF inhibitor therapy.
Wyluda EJ; Cheng J; Schell TD; Haley JS; Mallon C; Neves RI; Robertson G; Sivik J; Mackley H; Talamo G; Drabick JJ
Cancer Biol Ther; 2015; 16(5):662-70. PubMed ID: 25806780
[TBL] [Abstract][Full Text] [Related]
24. Expression analysis of PD-1 and Tim-3 immune checkpoint receptors in patients with vitiligo; positive association with disease activity.
Rahimi A; Hossein-Nataj H; Hajheydari Z; Aryanian Z; Shayannia A; Ajami A; Asgarian-Omran H
Exp Dermatol; 2019 Jun; 28(6):674-681. PubMed ID: 31046170
[TBL] [Abstract][Full Text] [Related]
25. Single-cell transcriptome analysis reveals TOX as a promoting factor for T cell exhaustion and a predictor for anti-PD-1 responses in human cancer.
Kim K; Park S; Park SY; Kim G; Park SM; Cho JW; Kim DH; Park YM; Koh YW; Kim HR; Ha SJ; Lee I
Genome Med; 2020 Feb; 12(1):22. PubMed ID: 32111241
[TBL] [Abstract][Full Text] [Related]
26. Vitiligo-like lesions occurring in patients receiving anti-programmed cell death-1 therapies are clinically and biologically distinct from vitiligo.
Larsabal M; Marti A; Jacquemin C; Rambert J; Thiolat D; Dousset L; Taieb A; Dutriaux C; Prey S; Boniface K; Seneschal J
J Am Acad Dermatol; 2017 May; 76(5):863-870. PubMed ID: 28094061
[TBL] [Abstract][Full Text] [Related]
27. In-depth plasma proteomics reveals increase in circulating PD-1 during anti-PD-1 immunotherapy in patients with metastatic cutaneous melanoma.
Babačić H; Lehtiö J; Pico de Coaña Y; Pernemalm M; Eriksson H
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32457125
[TBL] [Abstract][Full Text] [Related]
28. Microsatellite Instability Predicts Response to Anti-PD1 Immunotherapy in Metastatic Melanoma.
Roncati L
Acta Dermatovenerol Croat; 2018 Dec; 26(4):341-343. PubMed ID: 30665488
[TBL] [Abstract][Full Text] [Related]
29. Immune-related adverse events correlate with improved survival in patients undergoing anti-PD1 immunotherapy for metastatic melanoma.
Indini A; Di Guardo L; Cimminiello C; Prisciandaro M; Randon G; De Braud F; Del Vecchio M
J Cancer Res Clin Oncol; 2019 Feb; 145(2):511-521. PubMed ID: 30539281
[TBL] [Abstract][Full Text] [Related]
30. Harnessing autoimmunity (vitiligo) to treat melanoma: a myth or reality?
Ram M; Shoenfeld Y
Ann N Y Acad Sci; 2007 Sep; 1110():410-25. PubMed ID: 17911456
[TBL] [Abstract][Full Text] [Related]
31. Case Report: Immune checkpoint inhibitor-related vitiligo-like depigmentation in non-melanoma advanced cancer: A report of three cases and a pooled analysis of individual patient data.
Rao H; Guo Z; Wen X; Zeng X; Wu L; Huang L
Front Oncol; 2022; 12():1099108. PubMed ID: 36713515
[TBL] [Abstract][Full Text] [Related]
32. CD4
Xiao M; Xie L; Cao G; Lei S; Wang P; Wei Z; Luo Y; Fang J; Yang X; Huang Q; Xu L; Guo J; Wen S; Wang Z; Wu Q; Tang J; Wang L; Chen X; Chen C; Zhang Y; Yao W; Ye J; He R; Huang J; Ye L
J Immunother Cancer; 2022 May; 10(5):. PubMed ID: 35580929
[TBL] [Abstract][Full Text] [Related]
33. Transfer of efficient anti-melanocyte T cells from vitiligo donors to melanoma patients as a novel immunotherapeutical strategy.
Palermo B; Garbelli S; Mantovani S; Giachino C
J Autoimmune Dis; 2005 Aug; 2():7. PubMed ID: 16135249
[TBL] [Abstract][Full Text] [Related]
34. Age-associated changes in the immune system may influence the response to anti-PD1 therapy in metastatic melanoma patients.
Kasanen H; Hernberg M; Mäkelä S; Brück O; Juteau S; Kohtamäki L; Ilander M; Mustjoki S; Kreutzman A
Cancer Immunol Immunother; 2020 May; 69(5):717-730. PubMed ID: 32036449
[TBL] [Abstract][Full Text] [Related]
35. Immunotherapy-induced sarcoidosis in patients with melanoma treated with PD-1 checkpoint inhibitors: Case series and immunophenotypic analysis.
Lomax AJ; McGuire HM; McNeil C; Choi CJ; Hersey P; Karikios D; Shannon K; van Hal S; Carr U; Crotty A; Gupta SK; Hollingsworth J; Kim H; Fazekas de St Groth B; McGill N
Int J Rheum Dis; 2017 Sep; 20(9):1277-1285. PubMed ID: 28480561
[TBL] [Abstract][Full Text] [Related]
36. Melanoma and Vitiligo: In Good Company.
Failla CM; Carbone ML; Fortes C; Pagnanelli G; D'Atri S
Int J Mol Sci; 2019 Nov; 20(22):. PubMed ID: 31731645
[TBL] [Abstract][Full Text] [Related]
37. Vitiligo induced by immune checkpoint inhibitors in melanoma patients: an expert opinion.
Lommerts JE; Bekkenk MW; Luiten RM
Expert Opin Drug Saf; 2021 Aug; 20(8):883-888. PubMed ID: 33896329
[No Abstract] [Full Text] [Related]
38. Immune checkpoint inhibitor associated vitiligo and its impact on survival in patients with metastatic melanoma: an Italian Melanoma Intergroup study.
Guida M; Strippoli S; Maule M; Quaglino P; Ramondetta A; Chiaron Sileni V; Antonini Cappellini G; Queirolo P; Ridolfi L; Del Vecchio M; Cocorocchio E; Di Giacomo AM; Festino L; Merelli B; Occelli M; Brugnara S; Minisini A; Sava S; Tommasi S; De Summa S;
ESMO Open; 2021 Apr; 6(2):100064. PubMed ID: 33711672
[TBL] [Abstract][Full Text] [Related]
39. Immune Profile Analysis in Peripheral Blood and Tumor in Patients with Malignant Melanoma.
Saito R; Sawada Y; Nakamura M
Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33669410
[TBL] [Abstract][Full Text] [Related]
40. Immune phenotype of patients with stage IV metastatic inflammatory breast cancer.
Fernandez SV; MacFarlane AW; Jillab M; Arisi MF; Yearley J; Annamalai L; Gong Y; Cai KQ; Alpaugh RK; Cristofanilli M; Campbell KS
Breast Cancer Res; 2020 Dec; 22(1):134. PubMed ID: 33267869
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
